Mobile

A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011099-31

A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Assessment of the safety and tolerability of different dosages of IMO-2125 in combination with standard ribavirin compared to placebo and ribavirin or to Pegasys plus ribavirin.

Critère d'inclusion

  • Naïve Hepatitis C

Liens